Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells

Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells

US Patent 12318448 · Granted Jun 3, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CD47 targeted therapies for the treatment of infectious disease2025
Non-genotoxic conditioning regimen for stem cell transplantation2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies2025
Methods for achieving therapeutically effective doses of anti-CD47 agents2025
Methods for achieving therapeutically effective doses of anti-CD47 agents2025
Methods for treating myeloma by achieving therapeutically effective doses of ant2025
Methods for treating myeloma by achieving therapeutically effective doses of ant2025
Engraftment of stem cells with a combination of an agent that targets stem cells2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies2025
High affinity SIRP-alpha reagents and methods of using2025